141400-58-0 | 2-[(1-Methylpropyl)dithio]-1h-imidazole

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$31.00	$22.00
5mg	98%	in stock	$58.00	$41.00
10mg	98%	in stock	$87.00	$61.00
25mg	98%	in stock	$180.00	$126.00

Description

• Catalog Number: AD72285
• Chemical Name: 2-[(1-Methylpropyl)dithio]-1h-imidazole
• CAS Number: 141400-58-0
• Molecular Formula: C7H12N2S2
• Molecular Weight: 188.3136
• MDL Number: MFCD18086851
• SMILES: CCC(SSc1ncc[nH]1)C

Computed Properties

• Complexity: 111
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.3

Literature

• Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.

  Oncotarget 20120301

• Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.

  Journal of medicinal chemistry 20120112

• ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.

  PloS one 20120101

• A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.

  Cancer chemotherapy and pharmacology 20110301

• Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).

  Expert opinion on therapeutic patents 20110201

• Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.

  Bioorganic & medicinal chemistry 20080801

• Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.

  Bioorganic & medicinal chemistry letters 20080615

• 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation.

  Molecular cancer therapeutics 20080101

• Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner.

  PloS one 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070601

• A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070401

• A chemostat study of Streptomyces peucetius var. caesius N47.

  Applied microbiology and biotechnology 20070101

• Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.

  Current opinion in investigational drugs (London, England : 2000) 20061201

• The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

  The Journal of laboratory and clinical medicine 20060201

• Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.

  British journal of cancer 20050131

• The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.

  Cancer research 20040915

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040401

• Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women.

  Arthritis and rheumatism 20030701

• The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

  Molecular cancer therapeutics 20030301

• Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway.

  Molecular pharmacology 20021201

• The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.

  Carcinogenesis 20021001

• Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020305

• Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication.

  Cancer research 20011001